Being able to boast that his country has produced the world’s first COVID-19 vaccine is just what Russian President Vladimir Putin ordered, but it remains to be seen how safe and effective the product is.
The two-dose adenovirus vaccine, which will be called Sputnik V in a throwback to the Soviet Union’s pioneering Cold War satellite program, has been developed by Moscow's Gamaleya Institute.
But it appears to remain only in Phase I testing, with a Phase III trial yet to begin, according to World Health Organization (WHO) records.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze